Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTD/TPI plus fruquintinib versus fruquintinib alone for ctDNA-positive colorectal cancer after curative resection
jRCT2030260583Phase 2Not yet recruiting
- Sponsor
- Takeda
- Start
- Nov 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing FTD/TPI plus fruquintinib combination therapy with Fruquintinib monotherapy (2 arms). Primary endpoint: Disease-free survival. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2030260583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2030260583.